Neumora Therapeutics公布NMRA-511治疗阿尔茨海默病激越症状的1B期信号探索研究积极结果

美股速递
Jan 05

Neumora Therapeutics公司近日宣布,其针对阿尔茨海默病激越症状研发的药物NMRA-511,在1B期信号探索研究中取得了积极成果。这项研究旨在评估NMRA-511的安全性、耐受性及初步疗效信号,结果显示该药物在主要终点和关键次要终点上均表现出显著改善。数据表明NMRA-511有望为阿尔茨海默病相关的激越症状提供新的治疗选择,公司计划基于这些结果推进后续临床开发。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10